Inconclusive Diagnosis after Newborn Screening for Cystic Fibrosis

Abstract

by Anne Munck
Int. J. Neonatal Screen. 2020, 6(1), 19; https://doi.org/10.3390/ijns6010019 - 17 july 2022
Cited by 25 | Viewed by 3783
Abstract
An unintended consequence of newborn screening for cystic fibrosis (CF) is the identification of infants with a positive screening test but an inconclusive diagnostic testing. These infants are designated as CF transmembrane conductance regulator-related metabolic syndrome (CRMS) in the US and CF screen-positive, inconclusive diagnosis (CFSPID) in Europe. Recently, experts agreed on a unified international definition of CRMS/CFSPID which will improve our knowledge on the epidemiology and outcomes of these infants and optimize comparisons between cohorts. Many of these children will remain free of symptoms, but a number may develop clinical features suggestive of CFTR-related disorder (CFTR-RD) or CF later in life. Clinicians should to be prepared to identify these infants and communicate with parents about this challenging and stressful situation for both healthcare professionals and families. In this review, we present the recent publications on infants designated as CRMS/CFSPID, including the definition, the incidence across Europe, the assessment of the CFTR protein function, the outcomes with the rates of conversion to a final diagnosis of CF and their management. Full article
(This article belongs to the Special Issue Newborn Screening for Cystic Fibrosis)
► Show Figures
18 pages, 1944 KiB
Open AccessReview